Shinya Goto: DOAC vs Placebo in Intermediate Stroke Risk of AF in Single Country?
Shinya Goto, Director and Chairman in Metabolic Disease Research Center, shared a post on LinkedIn about a recent article by Daehoon Kim et al., published in The New England Journal of Medicine, adding:
“DOAC vs placebo in intermediate stroke risk of AF in single country?
Primary endpoint is combined safety or efficacy. NEJM shifted more for practice than keeping science?”
Title: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk
Authors: Daehoon Kim, Young Soo Lee, Jaemin Shim, Hee Tae Yu, Junbeom Park, Jin-Kyu Park, Il-Young Oh, Ki-Woon Kang, Eue-Keun Choi, Kyoung-Min Park, Hyoung-Seob Park, Dae-Hyeok Kim, Hyung Wook Park, Jun Kim, Jum-Suk Ko, Dongmin Kim, Jong-Youn Kim, Jin-Bae Kim, Jung-Hoon Sung, Tae-Hoon Kim, Jae-Sun Uhm, Hui-Nam Pak, Boyoung Joung
Other posts featuring Shinya Goto on Hemostasis Today.
-
Sep 25, 2026, 20:01Anand Gupta: Timing of DOAC Initiation in Newly Diagnosed Atrial Fibrillation
-
Sep 25, 2026, 19:56Steven Fein: A History of Blood Clots Doesn’t Mean a Healthy Pregnancy Is Out of Reach
-
Sep 25, 2026, 19:54Pedro Perez: “Provoked” VTE May Not Always Mean the Risk Disappears When the Provoking Event Does
-
Sep 25, 2026, 19:53Kemal Karaagac: Calcitriol May Reduce Thrombotic Risk in MASLD
-
Sep 25, 2026, 19:52The SINGLE-AF Trial Anticoagulation for Intermediate Stroke Risk – NEJM
-
Sep 25, 2026, 19:47Bryan Cotton: DOACs Versus Nothing When Stroke Risk Is Not Zero
-
Sep 25, 2026, 19:45Selin Yaman Seval: ITP Is More Than a Low Platelet Count
-
Sep 25, 2026, 19:44Cy R. Wilkins: Treating Chemotherapy-Induced Thrombocytopenia Beyond the Platelet Count
-
Sep 25, 2026, 19:42Mahitap Hossam: What the Platelet Count Cannot Show in ITP